Innovative Solutions for Effluent Treatment in Chinese Pharma Industry
Increasing levels of pollution have become a major cause of concern for Chinese industry and economy. API China 2015 will elaborate on the new environment protection policies in China to ensure sustainable development.
Bulk drug manufacturing processes in the pharmaceutical industry produces high-strength organic liquid waste water which requires specialized wastewater treatment and effluent management. These high strength industrial waste streams are often difficult to break down in conventional wastewater treatment processes. The high COD values and recalcitrant nature of the organic compounds present in these effluents require chemical innovations and separation technologies that will be demonstrated at API China 2015, to be held from May 15 to 18, 2015, at National Exhibition and Convention Center, Shanghai.
The four main types of harmful contaminants present in pharma effluents are oil and grease, pH, suspended solids, and biological oxygen demand (BOD) / chemical oxygen demand (COD) levels. However, pharma manufacturing companies, especially contract manufacturers (CMOs), operating out of more progressive provinces and municipalities in China should also consider the mineral content of their wastewater.
Low cost solutions at API China 2015
While there are a number of methods to identify and eliminate organic pollutants in pharmaceutical discharge, inorganic minerals cannot be easily destroyed. These require good quality evaporators and crystallizers which are expensive. Procure the new and low-cost equipment such as mineral crystallisers at API China 2015. These innovative technologies are particularly beneficial to small and medium sized enterprises and CMOs, who demand cutting-edge technology at economical prices.
In today’s highly competitive and globalized pharma industry, conventional wastewater treatments such as activated sludge are not sufficient for the complete removal of active pharmaceutical ingredients. As a result, complementary treatment methods such as membrane filtration, reverse osmosis and activated carbon are often used in conjunction with traditional methods for treatment of industrial wastewater. Apart from these, various other methods such as membrane bioreactor (MBR) technology, ozonation, and advanced oxidation processes will be demonstrated in great detail at API China 2015.
Shanghai Jiabo Clothing Science and Technology Co.,Ltd.
SCHLEE(Nan Jing) Refrigeration Machinery Manufacturing Co., Ltd.
Understanding Chinese Environment Policy
Among the leaders in the global pharma and medical services market, China is constantly evolving its environment protection policy. Thus, it is essential for global investors to understand the trends and dynamics of the Chinese approach towards pollution treatment and pharma effluent management. For this purpose, the organisers of API China 2015 will bring together the policy influencers and decision makers in a high-profile conference onGreen Manufacturing Practices for the Pharma Industry. As China seeks to play a greater role in the global movement towards Ecopharmacovigilance (EPV), API China 2015 will be the destination for you to promote your business in sync with global pharma trends. So visit http://www.api-china.com.cn/ today and register at.